CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

Charles River Laboratories International, Inc.

Equities

CRL

US1598641074

Market Closed - Nyse Other stock markets 21:00:02 20/01/2026 GMT			5-day change	1st Jan Change
218.19 ^USD	-0.69%		-0.37%	+9.38%

04:21pm	Jefferies Adjusts Price Target on Charles River Laboratories International to $255 From $205, Maintains Buy Rating	MT
01:21pm	Greenland, Tariffs, and the Quiet Revolt of the Bond Market

Transcript : Charles River Laboratories International, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08

Published on 05/14/2025 at 01:00 pm BST - Modified on 05/14/2025 at 04:40 pm BST

S&P Capital IQ

Presenter Speech
Michael Ryskin (Analysts)

And joining us for our next session is Charles River Labs. Thanks so much. We're joined by Birgit Girshick.

Format will be a

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Charles River Laboratories International, Inc.

04:21pm	Jefferies Adjusts Price Target on Charles River Laboratories International to $255 From $205, Maintains Buy Rating	MT
01:21pm	Greenland, Tariffs, and the Quiet Revolt of the Bond Market
10:10am	Analyst recommendations: Intel, Philip Morris, Duolingo, Netflix, SanDisk…
01-16	Citigroup Adjusts Price Target on Charles River Laboratories International to $265 From $200, Maintains Buy Rating	MT
01-13	Charles River Laboratories International, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM
01-13	Charles River Laboratories International Seeks Acquisitions	CI
01-13	Baird Adjusts PT on Charles River Laboratories International to $231 From $224, Keeps Outperform Rating	MT
01-13	Evercore ISI Adjusts PT on Charles River Laboratories International to $260 From $250, Maintains Outperform Rating	MT
01-12	Charles River Laboratories Reports Two Planned Acquisitions; Names Namandje Bumpus as Chief Scientific and Innovation Officer	MT
01-12	Charles River to buy Cambodia-based monkey supplier for $510 million	RE
01-12	Charles River Laboratories provides business updates	RE
01-12	Charles River Laboratories Names Dr. Namandjé N. Bumpus as Senior Vice President, Chief Scientific and Innovation Officer	CI
01-11	Charles River Laboratories International, Inc. exercised its option to acquire remaining 79% stake in PathoQuest SAS for ?51.6 million.	CI
01-11	Charles River Laboratories International, Inc. entered into agreement to acquire Assets of K.F. Ltd. from K.F. Ltd. for $510 million.	CI
01-11	Charles River Laboratories International, Inc. entered into agreement to acquire Assets of K.F. Ltd. from K.F. Ltd. for $510 million.	CI
01-09	Mizuho Adjusts Price Target on Charles River Laboratories International to $215 From $200, Maintains Neutral Rating	MT
01-08	Charles River Laboratories International, Inc. Announces Chief Executive Officer Changes	CI
01-08	Charles River Laboratories International, Inc. Announces Changes in Board	CI
01-08	Peace Was Cheaper
01-08	Charles River Laboratories International, Chair, President, CEO James Foster to Retire	MT
01-08	Charles River Laboratories announces planned retirement of James C. Foster	RE
12-19	Deutsche Bank Adjusts Price Target on Charles River to $230 From $205, Maintains Buy Rating	MT
12-18	Mizuho Adjusts Price Target on Charles River Laboratories International to $200 From $174, Maintains Neutral Rating	MT
12-15	Barclays Adjusts PT on Charles River Laboratories International to $215 From $210, Keeps Overweight Rating	MT
12-15	JPMorgan Adjusts Charles River Laboratories International PT to $190 From $165, Maintains Neutral Rating	MT